Clinical trials of modern oral testosterone undecanoate capsules showed no clinically significant liver toxicity.
At Longevity Benchmark, we review clinical trial records to separate historical drug reputations from current pharmaceutical mechanisms. Older oral androgens caused severe liver damage, creating widespread concern that continues to influence clinical discussions today.
The Verdict
Historical 17-Alpha-Alkylated Androgens and Hepatic Injury
The reputation of oral testosterone for causing liver damage originates entirely from older 17-alpha-alkylated androgens. Compounds such as methyltestosterone and fluoxymesterone undergo extensive first-pass metabolism in the liver. This metabolic pathway caused substantial hepatocellular stress and structural liver injury.
Clinical reports documented injuries ranging from cholestatic jaundice and peliosis hepatis to benign adenomas and hepatocellular carcinoma. The damage was severe. These documented toxicities led clinicians to avoid prescribing oral androgens for hormone replacement.
Those severe complications established the belief that any oral hormone pill would damage hepatic tissue. That historical pattern does not apply to unalkylated testosterone.
Lymphatic Absorption and First-Pass Hepatic Bypass
Modern oral testosterone undecanoate avoids extensive liver metabolism by absorbing directly into the intestinal lymphatic system. Chylomicrons transport the molecule into lymphatic vessels, which prevents direct uptake into the portal vein. This mechanism circumvents initial hepatic clearance.
A review in Sexual Medicine Reviews, volume 13, issue 1, page 33, examined this specific delivery mechanism. Lymphatic absorption rates reached 93.0% to 99.8%. Because portal vein delivery is avoided, the initial drug dose bypasses hepatic tissue.
Readers comparing commercial options can read our guide on compounded vs brand testosterone to see how delivery formats differ. The intestinal route represents a biological shift away from the metabolism of methyltestosterone.
Liver Enzyme Outcomes in Formulation Trials
Clinical trials evaluating oral testosterone undecanoate documented minor, infrequent transaminase elevations without evidence of cumulative hepatic injury. In the trial for Jatenzo, one patient experienced two transient episodes of elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Those elevations measured two to three times the upper limit of normal.
Two other trial participants showed AST or ALT increases below twice the normal ceiling. The changes resolved. A comparative review of Jatenzo, Tlando and Kyzatrex synthesized liver safety across these formulations.
For Tlando, a pooled analysis of 720 patients tracked post-treatment enzyme shifts. Shifts to abnormal values occurred in 3% of patients for ALT, 1% for AST, 0.3% for alkaline phosphatase (ALP), and 3% for gamma-glutamyl transferase (GGT). In the Kyzatrex trial, mean ALT changed by -0.4 U/L compared to +0.9 U/L in the control arm, while mean AST changed by +2.4 U/L against +1.0 U/L.
The review in Sexual Medicine Reviews concluded that increased liver function test values are not generally associated with oral testosterone undecanoate formulations. Furthermore, no clinically significant liver toxicities were noted in clinical trials.
| Formulation | Study Population or Design | Reported Liver Findings |
|---|---|---|
| Jatenzo | Clinical trial cohort | One patient showed two transient episodes of elevated ALT and AST at 2x to 3x upper limit of normal; two other patients had AST or ALT elevations below 2x upper limit of normal |
| Tlando | Pooled analysis of 720 patients | Shifts to abnormal at exit were 3% for ALT, 1% for AST, 0.3% for alkaline phosphatase, and 3% for GGT; no Hy's Law cases were detected |
| Kyzatrex | Clinical trial cohort with comparison arm | Mean change from baseline was ALT -0.4 U/L versus +0.9 U/L in comparison; AST was +2.4 U/L versus +1.0 U/L in comparison |
Regulatory Safety Screens and the Absence of Hy's Law Cases
Drug safety evaluations rely on Hy's Law as the accepted regulatory screen for drug-induced liver injury severity. Regulators use this benchmark during pharmaceutical development to detect whether a compound poses a risk of serious hepatic injury. It acts as an indicator threshold.
When a clinical trial reports no Hy's Law cases, it means no participant reached that combined safety threshold. The pooled analysis of 720 patients taking Tlando explicitly recorded zero Hy's Law cases during the study period.
Distinctions Between Hepatocellular and Cholestatic Markers
Interpreting an abnormal lab test requires distinguishing cellular leakage from overall hepatic capacity. Both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) reside inside liver cells. When cells suffer injury, these enzymes spill into the bloodstream.
They reflect cellular damage. A standard hepatic function panel evaluates these intracellular enzymes alongside markers of bile production and transport. In contrast to transaminases, alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) track cholestatic patterns.
Because older alkylated androgens caused cholestasis, evaluating both enzyme categories helps clinicians identify the specific pattern of any lab elevation. This separates membrane leakage from bile flow obstruction.
The Boxed Warning on Blood Pressure
The most prominent safety warning on modern oral testosterone capsules concerns cardiovascular metrics rather than hepatic injury. Jatenzo, Kyzatrex, and Tlando carry a boxed warning from the Food and Drug Administration (FDA) concerning the potential to increase blood pressure.
Official prescribing information for Jatenzo highlights this blood pressure elevation as its primary boxed safety consideration. This creates an instructive contrast for men investigating oral therapy. The serious warning focuses on blood pressure, not liver toxicity.
Boundaries of Current Clinical Evidence
While clinical trial data show reassuring hepatic profiles, important scientific boundaries remain. The authors of the review in Sexual Medicine Reviews emphasized that these medications are in early stages of development. They noted that ongoing surveillance is necessary.
Continued monitoring in larger real-world populations is required to establish long-term safety. Furthermore, the published sources do not include head-to-head comparisons evaluating liver outcomes between oral testosterone undecanoate and traditional administration routes.
Our analysis of TRT injections, cream, and pellets outlines how non-oral options behave, but direct comparative liver trials against oral capsules have not been run in these sources.
Considerations for Laboratory Monitoring and Follow-Up
Published literature on newer oral testosterone undecanoate formulations does not establish a standardized liver monitoring schedule. The clinical trials measured transaminases at baseline and specific study intervals, but the sources provide no formal clinical monitoring protocol. Men seeking a universal lab testing calendar will not find one in this trial data.
These findings do not describe outcomes for men with pre-existing hepatic disease, as that population is not characterized in these sources. What would change our assessment is future data from larger post-marketing registries documenting clinically significant liver toxicities or confirmed Hy's Law cases. Two questions are worth putting to a prescribing clinician: what liver markers were recorded at baseline, and will blood pressure be tracked alongside them?
Frequently Asked Questions
Does oral testosterone damage the liver?
Modern oral testosterone undecanoate formulations did not show clinically significant liver toxicities in clinical trials. Older 17-alpha-alkylated androgens like methyltestosterone caused severe hepatotoxicity, including jaundice, peliosis hepatis, and tumors, due to extensive first-pass liver metabolism. In contrast, modern testosterone undecanoate is absorbed primarily through the intestinal lymphatic system by chylomicrons, bypassing the portal vein and circumventing first-pass hepatic metabolism. A published review in Sexual Medicine Reviews showed that increased liver function test values are not generally associated with these newer formulations. However, the authors noted that these medications remain in early stages of development and require continued monitoring in larger real-world populations.
Is Jatenzo bad for your liver?
In clinical trials, Jatenzo was not associated with clinically significant liver toxicity. During trial monitoring, one patient showed two transient episodes of elevated ALT and AST measuring two to three times the upper limit of normal. Two other patients exhibited transaminase elevations that remained below twice the upper limit of normal. The trial did not report severe hepatic damage. The most serious safety warning on the Jatenzo label is not about the liver at all; it is an FDA boxed warning concerning the potential to increase blood pressure.
Why was old oral testosterone hepatotoxic but not the new kind?
The difference lies in chemical structure and the anatomical route of absorption. Older oral compounds were 17-alpha-alkylated androgens, such as methyltestosterone and fluoxymesterone. Because of their structure, they underwent extensive first-pass metabolism in the liver, leading to complications like cholestatic jaundice, peliosis hepatis, and liver neoplasms. Modern formulations use testosterone undecanoate. Instead of entering the portal vein, testosterone undecanoate is absorbed primarily by chylomicrons into the intestinal lymphatic system. The review reports lymphatic absorption rates between 93.0% and 99.8%. By bypassing initial liver metabolism, the medication is not routed through hepatic tissue first.
Does oral TRT raise ALT?
Oral testosterone undecanoate can cause minor, transient increases in alanine aminotransferase (ALT), but significant elevations are rare. In the Jatenzo trial, one patient had two temporary ALT elevations reaching two to three times normal limits, while two other participants had increases below twice normal limits. In pooled trial data for Tlando examining 720 patients, shifts to abnormal ALT values occurred in 3% of participants at exit. For Kyzatrex, the mean change in ALT from baseline was -0.4 U/L compared to +0.9 U/L in the control group. Overall, review data indicate that transaminase elevations are not generally associated with modern oral testosterone undecanoate.
What liver tests are run on testosterone therapy?
The sources on modern oral testosterone undecanoate do not specify a recommended liver monitoring interval or schedule for testosterone therapy. In clinical research trials, investigators tracked transaminases alongside cholestatic markers. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serve as markers of hepatocellular injury, reflecting enzyme release from damaged liver cells. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) are monitored because they reflect bile-duct integrity and cholestatic patterns. While trial protocols measured these markers at baseline and subsequent study intervals, no clinical guideline interval or universal testing schedule is provided in these sources.
Is oral testosterone safer than injections?
Published sources do not contain head-to-head clinical trials comparing the liver safety of oral testosterone undecanoate against injections or topical options. Clinical trials of modern oral capsules noted no clinically significant liver toxicities, and the formulations bypass first-pass hepatic metabolism via lymphatic absorption. However, researchers have not evaluated liver outcomes between oral undecanoate and injectable testosterone in direct comparative trials. Because comparative data have not been gathered in these sources, the available evidence cannot establish whether one administration route has a superior safety profile over another.
What is the boxed warning on oral testosterone?
The boxed warning on oral testosterone undecanoate formulations addresses the potential to increase blood pressure, not liver damage. The Food and Drug Administration (FDA) placed a boxed warning on Jatenzo, Tlando, and Kyzatrex regarding the potential to increase blood pressure. Although many patients assume oral hormones carry warnings for hepatic toxicity due to older anabolic steroids, the modern regulatory boxed warning focuses entirely on blood pressure. Liver function test abnormalities in clinical trials were generally infrequent, transient, and not deemed clinically significant toxicities.